Triesta Unit Of HCG To Combine With Strand Life Sciences

Strategic initiative creates integrated platform dedicated to next generation precision medicine

January 4, 2018 | Bengaluru, India

Healthcare Global Enterprises, Ltd. (HCG:NSE) today announced execution of definitive agreements for the business combination of its Triesta Sciences business unit (“Triesta”) with Strand Life Sciences Pvt. Ltd. (“Strand”).

Strand, established in 2000 as a spin-off from the Indian Institute of Science, is a bioinformatics company working with global technology vendors and research laboratories, and is the leader in genomic testing for cancer and inherited diseases in India. Triesta, a unit of HCG, offers comprehensive molecular diagnostics services and research services in the field of oncology.

The combination of Triesta and Strand creates an integrated platform with end to end capabilities in precision medicine – proprietary analytics, clinical research, access to the HCG biorepository, genomic technologies, assay development and validation and a network of laboratories offering a broad menu of tests.

Dr. B.S. Ajaikumar, Chairman and CEO of HCG, said “Strand and Triesta have been working together in bioinformatics and clinical genomics. We are now excited to combine our strengths and resources towards redefining precision medicine. In an era of data driven healthcare, Strand’s exceptional team of computer and life scientists with access to a well annotated clinical substrate, provides a unique opportunity to create exceptional value.”

Dr. Ramesh Hariharan, Founder and CEO of Strand, said “Triesta and HCG have been pioneers in bringing the latest advancements in molecular biomarkers into clinical practice in the country. Together we are well on the path to building Asia’s leading integrated analytics driven diagnostic and genomics research company. Through this alliance we will work together to be at the forefront of precision medicine”.

About Strand Life Sciences Pvt. Ltd.:

Strand Life Sciences is a global bioinformatics and genomic profiling company established in 2000. Strand is a leader in precision medicine diagnostics, aimed at empowering cancer care and enabling diagnosis of inherited diseases. Strand’s customers include leading global life science platform technology companies, research labs, as well as oncologists, paediatric specialists, geneticists and hospitals.

About HealthCare Global Enterprises Ltd.:

HealthCare Global Enterprises Ltd., headquartered in Bengaluru is a leading speciality healthcare provider with a focus on cancer care and reproductive medicine. Under the HCG brand, the company operates 20 comprehensive cancer centers across India and Africa, and has brought advanced cancer care to the doorstep of millions of people. “Milann”, India’s top ranked network of fertility centres is a subsidiary of HCG.

About Triesta Sciences:

Triesta, a unit of HCG, provides clinical reference laboratory services with a specialisation in oncology and operates laboratories in several HCG hospitals across India. Triesta also offers R&D services in the areas of clinical trial management and biomarker discovery and validation to pharmaceutical and biotechnology companies.

For further information, please contact:

Strand Press Releases

Strand In the News

Strand’s Media Coverage

Triesta Unit Of HCG To Combine With Strand Life Sciences